Chemical Name: beta-Escin, beta-Aescin
Cas No.: 11072-93-8
Description: White to off white powder
Assay: 96% to 102% HPLC
Aescin ( and Horse chestnut extracts) finds widespread use in the preventions and treatment of peripheral vascular disorders and in the treatment of venous stasis, Ulcus cruis, dysmenorrhoea and haemorrhoids. The antioedematous action of aescine is most pronounced and it exert a marked and prolonged antagonism against several types of local oedema induced by formalin, daxtran and ovalbumin. An example of use in the application of aescine of treatment of traumatic oedema of brain. There is usually a long latent period before aescine exert its maximum effect ( after approximately 16h in the rat paw oedema test).
While if can be administered intravenously or orally, aescine is also applied locally in the form of gel and salves.
Other area of application include the general strengthening of blood vessels ( Increased capillary resistance and decreased capillary permeability, i.e. capillaro-protective or venotonic properties);the treatment of varicose veins, bruises and hematomas and the prevention of thrombosis. One study, for example, found a clear improvement of venous tone (reduced dilation capacity) after oral administration of 90 mg horse chestnut extract to human volunteers .
The antiulcerogenic activity of aescine has been studied: the drug protest the gastric mucosa against lesions induced by absolute ethanol and also by pyloric ligature. At a dose of 50mg/kg body weight, the antiulcer activity of aescine is comparable with that of (80mg/kg) in rats, after oral administration.
Beta-Aescine is used in the cosmetic field for the prevention and treatment of panniculopatia oedemato-fibrosclerotica (cellulitis)
- 1. Rothkopf and vogel, 1976; Annoni et al. 1979
- 2. Diemath, 1981; Hemmer ,1985
- 3. Crielaard and Franchimont, 1988
- 4. Ehringer,1968 Marhuenda et al. 1993, Proserpio et al. 1980.